Article

Germline BRCA Mutation Affect the Clinical Outcomes of Metastatic Breast Cancer Treated with CDK4/6 Inhibitor: A Real-world Study

2025-07-31

Abstract excerpt

<title>Abstract</title> <p>Few clinical studies pay attention to clinical outcomes of CDK4/6 inhibitor in metastatic breast cancer with germline BRCA mutation. The present study aimed to explore whether germline BRCA mutation will affect the clinical efficacy of CDK4/6 inhibitor for metastatic breast cancer. Patients with HR+/HER-2- metastatic breast cancer who were treated with CDK4/6 inhibitor from January 2019...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 9a3b48d4-a826-574e-87ee-f837857fb4a6
DOI: 10.21203/rs.3.rs-7072445/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Germline BRCA Mutation Affect the Clinical Outcomes of Metastatic Breast Cancer Treated with CDK4/6 Inhibitor: A Real-world StudyDOI 10.21203/rs.3.rs-7072445/v1Read

Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) StudySemantic proximity Read

Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real‐world databaseSemantic proximity Read

Circulating genomic landscape following cyclin-dependent kinase 4/6 inhibitors exposure in HR + /HER2− metastatic breast cancer: a retrospective multi-institutional Consortium analysisSemantic proximity Read

BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testingSemantic proximity Read

TP53 mutation is associated with resistance to CDK4/6 Inhibitors, but not to Immune Checkpoint Inhibitors, in ER-positive/HER2-negative Breast Cancer: Real-World perspectiveSemantic proximity Read

Beyond PARP Inhibitors in Advanced Breast Cancer Patients with Germline BRCA1/2 Mutations: Focus on CDK4/6-Inhibitors and Data Review on Other Biological TherapiesSemantic proximity Read

The Present and Future of Clinical Management in Metastatic Breast CancerSemantic proximity Read

Assessment of a cancer genomic profile test for patients with metastatic breast cancer.Semantic proximity Read

Targeted next-generation sequencing detects a high frequency of potentially actionable mutations in metastatic breast cancers.Semantic proximity Read

Initial assessment of a cancer genomic profile test for patients with metastatic breast cancer: a retrospective studySemantic proximity Read

Post–CDK4/6 Inhibitor Therapeutic Approaches in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Current Evidence and Emerging Strategies - A Narrative ReviewSemantic proximity Read

478P Germline BRCA1/2 pathogenetic variants (gBRCA1/2 PV) affect outcome of hormone (HR)-positive HER2-negative metastatic breast cancer (MBC) patients (pts) treated with cyclin-dependent kinase 4/6 inhibitor (CDK 4/6i) plus endocrine therapy (ET): The BREAK studySemantic proximity Read